Literature DB >> 17468666

Impact of HIV-1 genetic diversity on plasma HIV-1 RNA Quantification: usefulness of the Agence Nationale de Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction test.

François Rouet1, Marie-Laure Chaix, Eric Nerrienet, Nicole Ngo-Giang-Huong, Jean-Christophe Plantier, Marianne Burgard, Martine Peeters, Florence Damond, Didier Koumavi Ekouevi, Philippe Msellati, Laurent Ferradini, Sandra Rukobo, Valérie Maréchal, Nilda Schvachsa, Lahcen Wakrim, Christian Rafalimanana, Benjamin Rakotoambinina, Jean-Paul Viard, Jean-Marie Seigneurin, Christine Rouzioux.   

Abstract

The high genetic diversity of HIV-1 has a major impact on the quantification of plasma HIV-1 RNA, representing an increasingly difficult challenge. A total of 898 plasma specimens positive for HIV-1 RNA by commercial assays (Amplicor v1.5; Roche Diagnostic Systems, Alameda, CA or Versant v3.0; Bayer Diagnostics, Emeryville, CA) were tested using the Agence Nationale de Recherches sur le SIDA second-generation (G2) real-time reverse transcriptase polymerase chain reaction (RT-PCR) test: 518 samples containing HIV-1 of known subtype, including 88 from 2 subtype panels and 430 harboring B (n = 266) and non-B (n = 164) group M HIV-1 subtypes from patients followed up in 2002 through 2005 at Necker Hospital (Paris, France), and 380 samples from 10 different countries (Argentina, Cambodia, Cameroon, Central African Republic, France, Ivory Coast, Madagascar, Morocco, Thailand, and Zimbabwe). HIV-1 RNA values obtained by G2 real-time PCR were highly correlated with those obtained by the Amplicor v1.5 for B and non-B subtypes (R = 0.892 and 0.892, respectively) and for samples from diverse countries (R = 0.867 and 0.893 for real-time PCR vs. Amplicor v1.5 and real-time PCR vs. Versant v3.0, respectively). Approximately 30% of specimens harboring non-B subtypes were underquantified by at least -0.51 log10 in Amplicor v1.5 versus 5% underquantified in G2 real-time PCR. Discrepant results were also obtained with subtype B samples (14% underquantified by Amplicor v1.5 vs. 7% by G2 real-time PCR). Similar percentages were observed when comparing results obtained with the G2 real-time PCR assay with those obtained using the Versant assay. Addressing HIV-1 diversity, continual monitoring of HIV-1 RNA assays, together with molecular epidemiology studies, is required to improve the accuracy of all HIV RNA assays.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17468666     DOI: 10.1097/QAI.0b013e3180640cf5

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  59 in total

1.  Most HIV type 1 non-B infections in the Spanish cohort of antiretroviral treatment-naïve HIV-infected patients (CoRIS) are due to recombinant viruses.

Authors:  Gonzalo Yebra; Miguel de Mulder; Leticia Martín; Carmen Rodríguez; Pablo Labarga; Isabel Viciana; Juan Berenguer; María Remedios Alemán; Juan Antonio Pineda; Federico García; Africa Holguín
Journal:  J Clin Microbiol       Date:  2011-12-07       Impact factor: 5.948

2.  Novel application of Locked Nucleic Acid chemistry for a Taqman assay for measuring diverse human immunodeficiency virus type 1 subtypes.

Authors:  Peilin Li; Theodore Ruel; Katsuya Fujimoto; Hiroyu Hatano; Steven Yukl; Leigh Anne Eller; Teri Liegler; Moses Kamya; Anne Gassasira; Grant Dorsey; Philip J Rosenthal; Diane V Havlir; Joseph K Wong
Journal:  J Virol Methods       Date:  2010-09-21       Impact factor: 2.014

3.  Prediction of treatment failure using 2010 World Health Organization Guidelines is associated with high misclassification rates and drug resistance among HIV-infected Cambodian children.

Authors:  Benjamin P Westley; Allison K DeLong; Chhraing S Tray; Dim Sophearin; Elizabeth M Dufort; Eric Nerrienet; Leeann Schreier; Joseph I Harwell; Rami Kantor
Journal:  Clin Infect Dis       Date:  2012-04-26       Impact factor: 9.079

4.  Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis.

Authors:  François-Xavier Blanc; Thim Sok; Didier Laureillard; Laurence Borand; Claire Rekacewicz; Eric Nerrienet; Yoann Madec; Olivier Marcy; Sarin Chan; Narom Prak; Chindamony Kim; Khemarin Kim Lak; Chanroeurn Hak; Bunnet Dim; Chhun Im Sin; Sath Sun; Bertrand Guillard; Borann Sar; Sirenda Vong; Marcelo Fernandez; Lawrence Fox; Jean-François Delfraissy; Anne E Goldfeld
Journal:  N Engl J Med       Date:  2011-10-20       Impact factor: 91.245

5.  A new human immunodeficiency virus derived from gorillas.

Authors:  Jean-Christophe Plantier; Marie Leoz; Jonathan E Dickerson; Fabienne De Oliveira; François Cordonnier; Véronique Lemée; Florence Damond; David L Robertson; François Simon
Journal:  Nat Med       Date:  2009-08-02       Impact factor: 53.440

Review 6.  Diagnosis of Human Immunodeficiency Virus Infection.

Authors:  Bharat S Parekh; Chin-Yih Ou; Peter N Fonjungo; Mireille B Kalou; Erin Rottinghaus; Adrian Puren; Heather Alexander; Mackenzie Hurlston Cox; John N Nkengasong
Journal:  Clin Microbiol Rev       Date:  2018-11-28       Impact factor: 26.132

7.  Single real-time reverse transcription-PCR assay for detection and quantification of genetically diverse HIV-1, SIVcpz, and SIVgor strains.

Authors:  Lucie Etienne; Sabrina Eymard-Duvernay; Avelin Aghokeng; Christelle Butel; Marjorie Monleau; Martine Peeters
Journal:  J Clin Microbiol       Date:  2012-12-19       Impact factor: 5.948

8.  Early HIV-1 diagnosis using in-house real-time PCR amplification on dried blood spots for infants in remote and resource-limited settings.

Authors:  Nicole Ngo-Giang-Huong; Woottichai Khamduang; Baptiste Leurent; Intira Collins; Issaren Nantasen; Pranee Leechanachai; Wasna Sirirungsi; Aram Limtrakul; Tasana Leusaree; Anne Marie Comeau; Marc Lallemant; Gonzague Jourdain
Journal:  J Acquir Immune Defic Syndr       Date:  2008-12-15       Impact factor: 3.731

9.  High survival and treatment success sustained after two and three years of first-line ART for children in Cambodia.

Authors:  Petros Isaakidis; Marie-Eve Raguenaud; Vantha Te; Chhraing S Tray; Kazumi Akao; Varun Kumar; Sopheak Ngin; Eric Nerrienet; Rony Zachariah
Journal:  J Int AIDS Soc       Date:  2010-03-21       Impact factor: 5.396

10.  Characterization of HIV-1 RNA forms in the plasma of patients undergoing successful HAART.

Authors:  Carlos A Lopez; Manuel Vazquez; Martin D Hill; Maria Del C Colon; Tirtsa Porrata-Doria; Ian C D Johnston; Eric Lorenzo
Journal:  Arch Virol       Date:  2010-04-23       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.